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Phthalates and Baby Boys
Potential Disruption of Human 
Genital Development
Epidemiologic research has revealed widespread
human exposure to phthalates, a class of chemicals
that appear in products as diverse as flexible plastics,
industrial solvents, and personal care products.
Rodent studies indicate that prenatal exposure to
some phthalates can disrupt normal male reproductive
tract development, causing effects such as reduced
anogenital (anus-to-penis) distance, undescended testi-
cles, and testicular abnormalities affecting function.
Although the phthalate concentrations that cause these
effects are quite high, changes in gene expression have
been seen at much lower levels, and concern exists that
human males might be similarly affected. The current
study, the first to investigate an association between
prenatal phthalate exposure and altered genital forma-
tion in humans, finds that these chemicals may indeed
contribute to such changes in boys exposed in utero
[EHP 113:1056–1061].
The research team gathered physical data on 134
boys aged 2–36 months who were enrolled with their
parents in the Study for Future Families II, a multicenter
study to investigate pre- and postnatal phthalate expo-
sure and potential related effects on development. The
researchers examined each boy’s testes and scrotum,
placement and size of each testis, penis size, and anogeni-
tal distance; none of the boys had obvious disease or
malformation. Urine samples collected during pregnancy
were available for 85 of the boys’ mothers. Sample analy-
sis quantified concentrations of nine phthalate metabo-
lites, which served as biomarkers of prenatal phthalate exposure.
To investigate correlation between prenatal phthalate exposure
and genital development, the researchers calculated an anogenital
index (AGI) by dividing each boy’s anogenital distance by his
weight. After considering how AGI varied as a function of age,
they calculated expected values and 25th and 75th percentiles.
Each boy’s AGI was categorized as either smaller than expected or
at least as large as expected. Based on the age-adjusted percentiles
for AGI, the boys were further categorized as having a short,
intermediate, or long AGI. The researchers also determined the
proportion of boys in these three groups who had normal testicu-
lar descent, scrotal size, and scrotal appearance.
More than 90% of the mothers had evidence of some phthalate
exposure. Urinary metabolite concentrations were categorized as indi-
cating low, intermediate, or high phthalate exposure. The researchers
tested whether a boy’s exposure level correlated with his odds of hav-
ing a short AGI while controlling for various confounding factors
such as maternal smoking and timing of urine sample collection.
They found that four metabolites—monoethyl phthalate,
mono-n-butyl phthalate, monobenzyl phthalate, and monoisobutyl
phthalate—were significantly associated with short AGI. The asso-
ciation was stronger when high levels of all four metabolites were
seen. Phthalate metabolite levels among the mothers of boys classi-
fied as having a short AGI were comparable to those measured in
one-quarter of the U.S. female population based on data from the
National Health and Nutrition Examination Survey published in
2004. The researchers also found that short AGI was associated
with incomplete descent of one or both testicles.
Although this study was small, the researchers conclude that,
consistent with animal studies, these data provide support for a
link between prenatal phthalate exposure and health effects in
humans. The researchers suggest that commonly used phthalates
may adversely affect male reproductive development, and indicate
that this possibility needs to be investigated more thoroughly in a
larger, more diverse population. –Julia R. Barrett
The Ups and Downs of 
Thyroid Hormone
PCBs May Reduce Levels in Pregnancy
Maintaining adequate levels of thyroid hormone (TH) during
pregnancy is critical for proper placental and fetal development.
Environmental contaminants including polychlorinated
biphenyls (PCBs), chlorinated pesticides, and mercury have been
shown to disrupt the endocrine system in both humans and ani-
mals, and experimental studies have shown that these chemicals
may decrease circulating TH levels during pregnancy. Now an
epidemiologic study by a team of Canadian researchers has
revealed that even low-level exposure to some of these chemicals
can alter TH status in expectant mothers, with unknown effects
[EHP 113:1039–1045]. 
PCBs and other persistent organohalogens are structurally
similar to TH, and are known to have a high affinity for
transthyretin, a TH carrier protein. Interference with maternal
TH may be one mechanism behind the observed learning and
behavioral deficits in children exposed to PCBs in the womb.
Most PCB congeners are transferred through the placenta to the
fetus such that fetal levels are 30–50% of maternal levels.
What’s up down there? New research shows an intriguing correlation between prenatal
exposure to phthalates and effects on anogenital distance in baby boys. Although similar
results have been shown in mice, this is the first such study in humans.The researchers checked the blood of 149 pregnant women for
a range of PCB congeners, several organochlorine pesticides, and
mercury. The researchers also measured levels of the major forms
of TH—T4 (the most common circulating form of TH) and T3
(the form of TH that regulates cellular metabolism)—as well as
thyroid-stimulating hormone (TSH), which is released from the
pituitary gland and stimulates production of TH. Cord blood sam-
ples were collected at birth and analyzed for the same hormones
and contaminants to estimate fetal exposure.
Results showed that total maternal T3 decreased with increas-
ing levels of three PCB congeners, the pesticide p,p´-DDE (a per-
sistent metabolite of DDT), the fungicide hexachlorobenzene, and
inorganic mercury. No association was found with methylmercury,
an organic form of mercury associated with neurologic deficits. In
cord blood, the only negative correlation was between free T4 and
inorganic mercury. 
The researchers had expected the women to have high PCB
and mercury levels because they lived in the polluted St. Lawrence
River basin and were likely to have eaten high levels of potentially
contaminated fish. But actual serum levels were 3–45 times lower
than those previously reported. The authors say this suggests that
pregnant women may be more sensitive than the general popula-
tion to chemicals that appear to reduce TH levels.
Recent epidemiologic research into PCBs’ effects on
human TH function has been inconsistent, and some stud-
ies have found no effect at exposure levels higher than those
in this study. But the current finding of a relationship at
such low levels indicates that more investigations are needed
in pregnant women, including monitoring of even subtle
environmental exposures that can disturb maternal and/or
fetal thyroid status. For this purpose, the biomarkers
should include not only TSH—which currently is
the only element of the thyroid system routinely
monitored in pregnant women—but all forms of TH.
–Valerie J. Brown
Thimerosal and 
Animal Brains
New Data for Assessing Human
Ethylmercury Risk
Since the 1930s, vaccines have contained
thimerosal, a mercury-based preservative
that breaks down to ethylmercury and thio-
salicylate in the body. By some calculations,
children given the usual schedule of vaccines
containing thimerosal receive ethylmercury
in doses exceeding the U.S. Environmental
Protection Agency’s guidelines for methyl-
mercury, a known neurotoxicant. Because of
the lack of pharmacokinetic and toxicity data
for ethylmercury, methylmercury has been
used as a reference for ethylmercury toxicity
based on the assumption that the two com-
pounds share similar toxicokinetic profiles.
However, a new animal study shows that
methylmercury is an inadequate reference for
ethylmercury due to significant differences in
tissue distribution, clearance rates, and ratios
of organic to inorganic mercury in the brain
[EHP 113:1015–1021]. 
During their first two years, children in the United States may
receive more than 20 routine vaccinations. The rise in childhood
autism has sparked concerns that thimerosal-derived ethylmercury
may be at least partly to blame for some of these cases—concerns
that are largely driven by awareness of methylmercury’s neurotox-
icity. Beginning in 1999 thimerosal-free versions of routine vac-
cines for children under age 6 started becoming available.
However, as of winter 2005, the flu vaccine still contained
thimerosal, and the preservative continues to be used in vaccines
in other countries. 
In the current study, researchers assigned 41 newborn mon-
keys to one of three exposure groups. Seventeen of the monkeys
were injected with vaccines spiked with thimerosal for a total
mercury dose of 20 micrograms per kilogram (µg/kg) at ages 0, 7,
14, and 21 days, mimicking the typical schedule of vaccines for
human infants. At the same ages, another 17 monkeys received 20
µg/kg methylmercury by stomach tube to mimic typical
methylmercury exposure. A third group of 7 monkeys served as
unexposed controls. 
The researchers drew blood from all monkeys prior to any
exposure and at other points prior to sacrifice, which occurred 2,
4, 7, or 28 days after the last dosing on day 21. Total mercury
concentrations were measured in blood samples, and total and
inorganic mercury concentrations were measured in brain
samples. Organic mercury concentrations were calcu-
lated from those values.
The initial absorption rate and
tissue distribution of mercury was simi-
lar in both exposed groups. However,
total mercury progressively accumu-
lated in the blood of methylmercury-
exposed monkeys and remained
detectable 28 days after the last
dose. Among thimerosal-
exposed monkeys, total mer-
cury in blood declined rapidly
between doses, and the
researchers estimated clear-
ance to be 5.4-fold higher
than in the methyl-
mercury group. In the
thimerosal group, the
half-life of total mer-
cury in blood was 6.9
days, compared to 19.1
days for the methyl-
mercury group.
Brain concentrations
of total mercury were
approximately 3–4 times
lower in the thimerosal
group than in the methyl-
mercury group, and total mer-
cury cleared more rapidly in the
thimerosal group (with a half-life
of 24.2 days versus 59.5 days).
However, the proportion of inorganic
mercury in the brain was much higher
in the thimerosal group (21–86%
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A sticky situation. New data show that
using methylmercury as a reference for
calculating risk from ethylmercury in vac-
cines may be fraught with problems.of total mercury) compared to the methylmercury group (6–10%).
Brain concentrations of inorganic mercury were approximately
twice as high in the thimerosal group compared to the methylmer-
cury group. Inorganic mercury remains in the brain much longer
than organic mercury, with an estimated half-life of more than a
year. It’s not currently known whether inorganic mercury presents
any risk to the developing brain.
Given these findings, the researchers caution that risk assess-
ments for thimerosal based on studies using blood mercury mea-
surements may not be valid, depending on the design of the study.
Further, the observed differences in distribution and breakdown of
mercury compounds between exposed groups indicate that
methylmercury is not a suitable model for thimerosal toxicity. 
The researchers emphasize, however, that the risks associated
with low-level exposures to inorganic mercury in the developing
brain are unknown, and they describe other research linking per-
sistent inorganic mercury exposure with increased activation of
microglia in the brain, an effect recently reported in children with
autism. They recommend further research focused specifically on
the biotransformation of thimerosal and its neurotoxic potential.
–Julia R. Barrett
Pancreatic Effects of EDCs 
Low Doses Can Impair Glucagon Secretion
Endocrine-disrupting chemicals (EDCs) mimic naturally occur-
ring hormones such as estrogen by occupying hormone receptors
and triggering a reaction in the body. Interactions of EDCs with
the classical (nuclear) estrogen receptors ER-α and ER-β have
been well characterized, and there is also growing knowledge
regarding interactions with nonclassical receptors (found else-
where, as on the cell membrane). Both classical and nonclassical
estrogen receptors occur throughout the body, reflecting the many
roles played by estrogen in regulating
the body’s functions. This widespread
presence also translates to myriad ways
that EDCs could potentially interfere
with health. New research now suggests
that pancreatic cells are affected by
EDC exposure, with potential health
consequences [EHP 113:969–977].
Although the pancreas might seem
an unlikely estrogen target, it bears
classical and nonclassical receptors on
both α- and β-cells in the islet of Lan-
gerhans. These cells secrete glucagon
and insulin, respectively, hormones
that regulate blood glucose levels,
among other functions. In α-cells, low
blood glucose causes increased calcium
oscillations—or fluctuations in intra-
cellular calcium concentrations—via a
transmembrane channel; these oscilla-
tions trigger glucagon secretion. 
Glucagon regulates functions in fat
tissue and in the liver, brain, kidney,
intestine, and pancreas. The primary
role of glucagon is to enhance glucose
synthesis and release in the liver.
Secondary roles include increased fatty
acid release from fat cells and appetite
control in the central nervous system.
These responses to low glucose can be
suppressed by the endogenous estrogen 17β-estradiol and, as
demonstrated in the current report, by EDCs as well. 
The research team focused on two EDCs: bisphenol A, a compo-
nent of such products as polycarbonate plastic and dental sealants,
and diethylstilbestrol, a synthetic estrogen used from the 1940s to the
1970s to prevent miscarriage. Based on previous research, the
researchers hypothesized that 17β-estradiol and the EDCs would
bind to nonclassical estrogen receptors on the membrane of
glucagon-producing α-cells and activate a sequence of secondary
messengers within the cell, leading to control of the transmembrane
calcium channel and related calcium oscillations.
To test the hypothesis, they examined freshly isolated mouse pan-
creatic islets and subjected samples to physiological assays.
Competitive binding assays indicated that 17β-estradiol, bisphenol
A, and diethylstilbestrol shared a common membrane-binding site.
This binding was unaffected in competitive assays using the pure
antiestrogen ICI182,780, which inhibits only classical ER–mediated
effects. This result indicated that the common binding site was a
nonclassical membrane estrogen receptor. Immunocytochemical
assays confirmed that 17β-estradiol and the EDCs bound to
glucagon-producing α-cells. 
Further assays of bisphenol A alone used compounds known to
inhibit steps along the suspected pathway. These assays provided evi-
dence that 17β-estradiol and bisphenol A affected the sequence of
cellular reactions that ultimately regulates calcium oscillations. These
oscillations were tracked by laser scanning confocal microscopy.
The researchers note that there is some debate regarding the
EDC concentrations necessary to produce biological effects in
humans and animals. Their study indicates that EDC doses in the
nanomolar range are sufficient to suppress calcium oscillations,
potentially affecting secretion of glucagon. The possible conse-
quences of this suppression could include changes in glucose and
lipid metabolism and reduced use of stored glucose and fat, which
could contribute to obesity. –Julia R. Barrett
Science Selections
A 544 VOLUME 113 | NUMBER 8 | August 2005 • Environmental Health Perspectives
P
h
o
t
o
d
i
s
c Organ at risk? Low doses of the endocrine-disrupting chemicals diethylstilbestrol and bisphenol A
were shown to affect pancreatic cells, potentially suppressing secretion of glucagon. This hormone reg-
ulates blood glucose levels and plays a role in appetite control and release of fatty acids from fat cells. 